Regulation of HER2/Neu promoter activity by the ETS transcription factor, ER81

被引:38
作者
Bosc, DG [1 ]
Janknecht, R [1 ]
机构
[1] Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA
关键词
cancer; CBP; ER81; HER2/Neu; MAP kinase; p300; transcription;
D O I
10.1002/jcb.10205
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Overexpression of the HER2/Neu receptor is correlated to a poor prognosis in tumor patients and leads to stimulation of mitogen-activated protein kinase (MAPK) signaling pathways, which in turn activate transcription factors, such as the ETS protein ER81. Here, we have analyzed whether, on the other hand, ER81 may regulate the Her2/ neu gene. Indeed, ER81, together with its co-activators, p300 and CBP, activates the Her2/neu promoter, and this activation is enhanced upon stimulation of MAPK pathways as well as by oncogenic HER2/Neu protein. Furthermore, ER81 interacts with one ETS binding site in the Her2/neu promoter, whose mutation decreases ER81-mediated transcription. Activation of the Her2/neu promoter is also diminished upon mutation of MAPK-dependent phosphorylation sites in ER81 or upon deletion of ER81 transactivation domains. In addition, the ER81 DNA-binding domain on its own functions as a dominant-negative molecule, effectively repressing any stimulation of the Her2/neu promoter. Altogether, our results show that ER81 is a component of a positive regulatory feedback loop, in which the HER2/Neu protein activates ER81, as well as p300/CBP via MAPKs causing the upregulation of the Her2/neu gene. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:174 / 183
页数:10
相关论文
共 56 条
[1]   Phosphorylation by p44 MAP kinase/ERK1 stimulates CBP histone acetyl transferase activity in vitro [J].
Ait-Si-Ali, S ;
Carlisi, D ;
Ramirez, S ;
Upegui-Gonzalez, LC ;
Duquet, A ;
Robin, P ;
Rudkin, B ;
Harel-Bellan, A ;
Trouche, D .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 262 (01) :157-162
[2]   A FAMILY OF TRANSCRIPTIONAL ADAPTER PROTEINS TARGETED BY THE E1A ONCOPROTEIN [J].
ARANY, Z ;
NEWSOME, D ;
OLDREAD, E ;
LIVINGSTON, DM ;
ECKNER, R .
NATURE, 1995, 374 (6517) :81-84
[3]  
Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO
[4]  
2-H
[5]   A SINGLE AUTOPHOSPHORYLATION SITE CONFERS ONCOGENICITY TO THE NEU/ERBB-2 RECEPTOR AND ENABLES COUPLING TO THE MAP KINASE PATHWAY [J].
BENLEVY, R ;
PATERSON, HF ;
MARSHALL, CJ ;
YARDEN, Y .
EMBO JOURNAL, 1994, 13 (14) :3302-3311
[6]   HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer [J].
Benz, CC ;
OHagan, RC ;
Richter, B ;
Scott, GK ;
Chang, CH ;
Xiong, XH ;
Chew, K ;
Ljung, BM ;
Edgerton, S ;
Thor, A ;
Hassell, JA .
ONCOGENE, 1997, 15 (13) :1513-1525
[7]   The PEA3 Ets transcription factor comprises multiple domains that regulate transactivation and DNA binding [J].
Bojovic, BB ;
Hassell, JA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (06) :4509-4521
[8]   HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1 [J].
Bosc, DG ;
Goueli, BS ;
Janknecht, R .
ONCOGENE, 2001, 20 (43) :6215-6224
[9]   THE DEVELOPMENTALLY-REGULATED TRANSCRIPTION FACTOR AP-2 IS INVOLVED IN C-ERBB-2 OVEREXPRESSION IN HUMAN MAMMARY-CARCINOMA [J].
BOSHER, JM ;
WILLIAMS, T ;
HURST, HC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (03) :744-747
[10]  
Bosher JM, 1996, ONCOGENE, V13, P1701